<a href="https://laohu8.com/S/PEN">Penumbra Inc</a>. Completes Enrollment for Groundbreaking STORM-PE Trial, Pioneering Computer Assisted Vacuum Thrombectomy for Pulmonary Embolism Treatment
Penumbra, Inc. has announced the completion of enrollment for the STORM-PE clinical trial, a groundbreaking study evaluating the efficacy of computer assisted vacuum thrombectomy (CAVT™) using Penumbra's Lightning Flash™ combined with anticoagulation, compared to anticoagulation alone in treating acute intermediate-high risk pulmonary embolism. The trial enrolled 100 patients and aims to provide high-quality evidence on the role of CAVT in improving right heart function and clinical outcomes. The completion of enrollment marks a significant milestone in the trial, which is conducted in partnership with The PERT Consortium®. Results of the STORM-PE trial have not yet been presented. For further details, visit https://www.penumbrainc.com/storm-pe-trial.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Penumbra Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF10486) on June 16, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。